HIV post-exposure prophylaxis: Enhancing its pharmaco-economic profile by discriminate prescribing

AIDS

Volumn 16, Issue 8, 2002, Pages 1177-1179

  Postma, Maarten J ^a,d   Bos, Jasper M ^a   De Jong Van Den Berg, Lolkje T W ^a   Tramarin, Andrea ^b   Van Bergen, Jan E A M ^c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b SAN BORTOLO HOSPITAL   (Italy)

^c Foundation for STD Control   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Adverse drug reactions; Discriminate prescribing; Guidelines; Pharmaco economics; Post exposure prophylaxis

Indexed keywords

ANTIRETROVIRUS AGENT;

COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; DRUG INDICATION; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT INDICATION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS;

EID: 0037165906     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200205240-00012     Document Type: Editorial

References (14)

1. Spare non-occupational HIV post-exposure (PEP) by active contacting and testing the source person
2. Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV
3. Cost effectiveness of human immunodeficiency virus postexposure prophylaxis for healthcare workers
4. Cost-effectiveness of HIV screening of patients attending clinics for sexually transmitted diseases in Amsterdam
5. Public Health Service statement on management of possible sexual, injecting drug use, or other nonoccupational exposure to HIV, including considerations related to anti-retroviral therapy
6. Post-exposure prophylaxis after occupational and non-occupational exposures to HIV: An overview of the policies implemented in 27 European countries
7. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV
8. Updated US Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis
9. Nevirapine should not be prescribed for needlestick injuries
10. Cost-effectiveness of chemoprophylaxis after Occupational exposure to HIV
11. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV
12. Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: Identification and characterization of the source of exposure